Mr. Mahadi Hasan | University of South Dakota | United States
Mr. Mahadi Hasan completed his BS and MS from the University of Dhaka, Bangladesh, and worked as a lecturer for five years before relocating to the United States for a second master’s degree. He is currently a Ph.D. candidate in the Materials Chemistry program at the University of South Dakota. His research focuses on the targeted delivery of anticancer drugs using smart nano-cargo of mineral particles, emphasizing synthesis modification and surface functionalization of nanomaterials. He developed a method for delivering veratridine into colorectal cancer cells using casein-coated carboxylated mesoporous silica nanoparticles and discovered a spongelike morphology of calcium citrate particles and calcium carbonate submicroparticles (400–700 nm), which are advantageous for drug delivery applications. He has also developed an undergraduate laboratory experiment modeling drug discovery and targeted delivery using calcium-based particles. His completed and ongoing projects include mesoporous silica nanoparticle-based targeted drug delivery against colorectal cancer, PEGylated MSNs and calcium carbonate submicroparticles as drug carriers, calcium carbonate nanoparticles as mineral sunscreen against skin cancer, and hydroxyapatite nanorods for gene transfer in plants. He has published 1 SCI-indexed article in Cancers (2025) on liver-specific nanoparticle-mediated delivery and MMP-triggered release of veratridine to target metastatic colorectal cancer, collaborating with Professor Dr. Khosrow Rezvani. He is an ACS member since 2022 and works at the intersection of organic chemistry, materials chemistry, nanotechnology, drug delivery, and biomedical sciences. His research contributes significantly to oncology by creating mineral particle-based gated drug delivery systems, advancing both fundamental knowledge and practical therapeutics. His work has 1 publication, with citations accumulating and an h-index of 1, reflecting his growing influence in nanomedicine and targeted therapeutics. Through interdisciplinary collaboration, he is moving toward commercialization of his technology, highlighting the translational impact of his work. His innovations provide practical solutions for colorectal cancer treatment while educating the next generation of chemists and biomedical scientists. His contributions span drug delivery, nanomaterial synthesis, particle morphology engineering, biomedical applications, and translational therapeutics. By integrating chemistry and biomedical sciences, he advances health innovation and sustainable therapeutic strategies. His research has established a platform for further exploration of mineral particle-based nanomedicine. His work demonstrates a unique combination of creativity, scientific rigor, and translational potential in cancer therapeutics, materials chemistry, and nanotechnology. He continues to collaborate with biomedical scientists to optimize nanoparticle-based drug delivery systems for oncology. His developments in mineral particle engineering offer novel approaches for targeted, efficient, and controlled drug delivery. The focus on spongelike calcium citrate and submicroparticles ensures high payload capacity, biocompatibility, and therapeutic efficacy. He emphasizes interdisciplinary approaches that bridge chemistry, materials science, and biomedical applications. His contributions are fostering a new generation of mineral-based nanomedicine platforms with significant health impact.
Featured Publications
Hasan, M., Eikanger, M., Sane, S., Wijewardhane, K. S. K., Slunecka, J. L., Freeling, J., Rezvani, K., & Sereda, G. (2025). Liver-specific nanoparticle-mediated delivery and MMP-triggered release of veratridine to effectively target metastatic colorectal cancer. Cancers, 17(19), 3253.
Hasan, M., Eikanger, M., Sane, S., Wijewardhane, K. S. K., Slunecka, J., Freeling, J., Rezvani, K., & Sereda, G. (2025). Liver-specific nanoparticle-mediated delivery and MMP-triggered release of veratridine, a potent pro-apoptotic molecule, to effectively target metastatic colorectal cancer [Preprint]. Preprints.